Want to see IN:ANUHPHR full AI Analyst Report?
ANUHPHR Stock Chart & Stats
₹77.53
-₹3.95(-1.77%)
At close: 4:00 PM EST
₹77.53
-₹3.95(-1.77%)
Day’s Range― - ―
52-Week Range₹66.72 - ₹99.50
Previous CloseN/A
Volume12.53K
Average Volume (3M)25.20K
Market Cap
₹8.18B
Enterprise Value₹2.83B
Total Cash (Recent Filing)₹135.33M
Total Debt (Recent Filing)₹2.27M
Price to Earnings (P/E)18.6
Beta0.71
Next Earnings
Nov 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.84%
Share Statistics
EPS (TTM)2.00
Shares Outstanding100,224,000
10 Day Avg. Volume10,133
30 Day Avg. Volume25,204
Financial Highlights & Ratios
PEG Ratio-1.25
Price to Book (P/B)1.91
Price to Sales (P/S)0.87
P/FCF Ratio-61.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthStrong revenue expansion demonstrates continued ability to grow sales across the API portfolio and serve pharmaceutical manufacturing customers. If maintained, this scale can support operating leverage, strengthen market presence, and provide a durable base for future earnings growth.
Exceptionally Low LeverageNear-zero leverage gives Anuh Pharma substantial financial flexibility and reduces exposure to interest costs and refinancing pressure. A conservative balance sheet can help the company withstand operating volatility while preserving capacity to fund production, compliance, and growth initiatives.
Growing Asset And Equity BaseSteady growth in assets and equity indicates that the business has expanded its underlying financial base rather than relying heavily on debt. This supports resilience and provides a stronger platform for sustaining API manufacturing capacity through changing industry conditions.
Bears Say
Negative Operating And Free Cash FlowNegative operating and free cash flow creates a meaningful challenge to earnings quality because reported profit is not currently converting into cash. Continued weakness could constrain internally funded investment and increase reliance on working-capital improvement or external financing.
Material Margin CompressionThe sharp decline in gross and net margins reduces the amount of revenue retained as profit and weakens the durability of current earnings. Unless margins recover, higher sales may deliver limited profit growth and leave the company more exposed to cost or product-mix pressure.
Net Income Declined Despite Higher SalesFalling net income while revenue rises signals that growth is becoming less profitable, whether from product mix, costs, or both. This weakens operating efficiency and makes future earnings expansion dependent on restoring profitability rather than relying only on continued sales growth.
Anuh Pharma Limited News
ANUHPHR FAQ
What was Anuh Pharma Limited’s price range in the past 12 months?
Anuh Pharma Limited lowest stock price was ₹66.72 and its highest was ₹99.50 in the past 12 months.
What is Anuh Pharma Limited’s market cap?
Anuh Pharma Limited’s market cap is ₹8.18B.
When is Anuh Pharma Limited’s upcoming earnings report date?
Anuh Pharma Limited’s upcoming earnings report date is Nov 13, 2026 which is in 31 days.
How were Anuh Pharma Limited’s earnings last quarter?
Anuh Pharma Limited released its earnings results on Aug 07, 2026. The company reported ₹1.14 earnings per share for the quarter.
Is Anuh Pharma Limited overvalued?
According to Wall Street analysts Anuh Pharma Limited’s price is currently Overvalued.
Does Anuh Pharma Limited pay dividends?
Anuh Pharma Limited pays a Annually dividend of ₹1.5 which represents an annual dividend yield of 1.84%. See more information on Anuh Pharma Limited dividends here
What is Anuh Pharma Limited’s EPS estimate?
Anuh Pharma Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Anuh Pharma Limited have?
Anuh Pharma Limited has 100,224,000 shares outstanding.
What happened to Anuh Pharma Limited’s price movement after its last earnings report?
Anuh Pharma Limited reported an EPS of ₹1.14 in its last earnings report. Following the earnings report the stock price went up 1.166%.
Which hedge fund is a major shareholder of Anuh Pharma Limited?
Currently, no hedge funds are holding shares in IN:ANUHPHR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Anuh Pharma Limited
Anuh Pharma Ltd. is an Indian enterprise specializing in the manufacturing and distribution of bulk drugs and various chemical compounds. The company provides a comprehensive selection of active pharmaceutical ingredients (APIs), encompassing macrolides, anti-tuberculosis agents, antibacterials, anti-asthmatics, anti-diabetic compounds, intermediates, expectorants, quinolones, anti-malarials, anti-gout medications, antibiotics, anti-platelet drugs, and antihistamines. Additionally, it produces corticosteroids valued for their anti-inflammatory, immunosuppressant, anti-pruritic, and anti-mitotic actions. Anuh Pharma is also engaged in developing new products within therapeutic categories such as coagulants, gastrointestinal treatments, anticonvulsants, and cholesterol-reducing medications. Its products are sold both domestically and to international markets. The company, established in 1960, maintains its headquarters in Mumbai, India.
Technical Analysis
Albert David Ltd
―
Kilitch Drugs (India) Limited
―
Sigachi Industries Limited
―
Wanbury Limited
―
Zim Laboratories Ltd.
―